Feldan Therapeutics Announces Issuance of First Patent for its Peptide-Based Protein Delivery Technology, the Feldan Shuttle

QUEBEC CITY, Aug. 22, 2017 /CNW Telbec/ - Feldan Therapeutics, Inc. today announced the issuance of its first patent covering the company's technology, the Feldan Shuttle platform. The United States Patent and Trademark Office (USPTO) granted Feldan Therapeutics the patent on August 22nd, 2017. The Feldan Shuttle platform is a peptide-based delivery method that allows the introduction of foreign proteins inside cells. This technology is applicable to the development of cell therapies and genome-modified cell therapies. 

The new patent, U.S. Patent No. 9738687, is entitled "Polypeptide-based shuttle agents for improving the transduction efficiency of polypeptide cargos to the cytosol of target eukaryotic cells, uses thereof, methods and kits relating to same" and includes claims directed to use of synthetic peptides for delivery of cargo to cells. Other claims of the patent specifically protect the use of the Shuttle peptide for the delivery of various cargos such as transcription factors, nucleases, cytokines, hormones, growth factors and antibodies to different cell types.

"Our mission is to develop regenerative medicine therapeutic applications based on the Feldan Shuttle platform," said Francois-Thomas Michaud. PhD. Eng., Chief Executive Officer of Feldan Therapeutics. "In this context, the issuance of this patent brings us one step closer to our objective, bringing our technology to the clinic as quickly and as efficiently as possible.  We have great confidence in the potential of our technology to promote the development of life-saving therapeutic applications, and this new patent provides a valuable protection for our Shuttle platform."

About Feldan Therapeutics

Feldan Therapeutics has developed a peptide-based technology platform, the Feldan Shuttle, for direct delivery of proteins inside cells. The platform has been successfully used on several cell types (including human primary cells which are the center of most cell therapies) allowing the delivery of nucleases, transcription factors and antibodies. The Shuttle can overcome delivery obstacles in the context of therapeutic use by providing a safe and efficient approach that alleviates manipulation complexity and that is associated with low regulatory burden. Feldan Therapeutics' mission is to develop regenerative medicine therapeutic applications based on the Feldan Shuttle platform. Feldan Therapeutics has generated a pipeline of clinical applications taking advantage of the unique characteristics of the Shuttle.

For further information: www.feldan.com

SOURCE Feldan Therapeutics

For further information: Corporate Contact: Francois-Thomas Michaud, PhD. Eng., CEO, Feldan Therapeutics, Inc., T: 418 872 7277, [e-mail]